Ghrelin receptor modulators and their therapeutic potential

Future Medicinal Chemistry

Volumn 1, Issue 1, 2009, Pages 157-177

  Costantino, Luca ^a   Barlocco, Daniela ^a  

^a UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 DIAMINOPYRIMIDINE DERIVATIVE; ANTIDIABETIC AGENT; ANTIOBESITY AGENT; GHRELIN; GHRELIN RECEPTOR; GROWTH HORMONE SECRETAGOGUE; ISOXAZOLE; OXINDOLE; PIPERAZINE; PRALMORELIN; QUINAZOLINONE DERIVATIVE; SPIRO(INDOLINE 3,4 PIPERIDINE) DERIVATIVE; TETRALIN DERIVATIVE; TETRAZOLE DERIVATIVE; TRIAZOLE; UNCLASSIFIED DRUG;

BIOSYNTHESIS; BODY COMPOSITION; CHEMICAL STRUCTURE; FOOD INTAKE; GROWTH HORMONE RELEASE; HUMAN; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN FUNCTION; REVIEW; STRUCTURE ACTIVITY RELATION;

AZOLES; DRUG DISCOVERY; GHRELIN; HUMANS; PIPERAZINES; PIPERIDINES; RECEPTORS, GHRELIN; SPIRO COMPOUNDS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 77953426150     PISSN: 17568919     EISSN: None     Source Type: Journal    
DOI: 10.4155/fmc.09.9     Document Type: Review

References (122)

1. Kojima M, Kangawa K. Ghrelin: structure and function. Physiol. Rev. 85, 495-522 (2005).
2. Nakazato M, Muratami N, Date Y et al. A role for ghrelin in the central regulation of feeling. Nature 409, 194-198 (2001).
3. Takaya K, Ariyasu H, Kanamoto N et al. Ghrelin strongly stimulates GH release in humans. J. Clin. Endocrinol. Metab. 85, 4908-4911 (2000).
4. Tschop M, Smiley DL, Heiman ML. Ghrelin induces adiposity in rodents. Nature 407, 908-913 (2000).
5. Asakawa A, Innui A, Kaga T et al. Antagonism of ghrelin receptor reduces food intake and body weight gain in mice. Gut 52, 947-952 (2003).
6. Lall S, Tung LYC, Ohllson C, Jansson JO, Dickson SL. Growth hormone (GH)- independent stimulation of adiposity by GH secretagogues. Biochem. Biophys. Res. Commun. 280, 132-138 (2001).
7. Lawrence CB, Snape AC, Baudoin FMH, Luckman SM. Acute central ghrelin and GH secretagogues induce feeding and activate brain appetite centers. Endocrinology 143, 155-162 (2002).
8. Kamegai J, Tamura H, Shimizu T, Ishii S, Sugihara H, Wakabayashi I. Chronic central infusion of ghrelin increases hypothalamic neuropeptide Y and Agouti-related protein mRNA levels and body weight in rats. Diabetes 50, 2438-2443 (2001).
9. Rudd JA, Ngan MP, Wai MK et al. Anti-emetic activity of ghrelin in ferrets exposed to the cytotoxic anti-cancer agent cisplatin. Neurosci. Lett. 392, 79-83 (2006).
10. Volante M, Allia E, Gugliotta P et al. Expression of ghrelin and of the GH secretagogue receptor by pancreatic islet cells and related endocrine tumors. J. Clin. Endocrinol. Metab. 87, 1300-1308 (2002).
11. Adeghate E, Ponery AS. Ghrelin stimulates insulin secretion from the pancreas of normal and diabetic rats. J. Neuroendocrinol.14, 555-560 (2002).
12. Wierup N, Svensson H, Mulder H, Sundler F. The ghrelin cell: a novel developmentally regulated islet cell in the human pancreas. Regul. Pept. 107, 63-69 (2002).
13. Date Y, Nakazato M, Hashiguchi S et al. Ghrelin is present in pancreatic a-cells of humans and rats and stimulates insulin secretion. Diabetes 51, 124-129 (2002).
14. Wierup N, Yang S, McEvilly RJ, Mulder H, Sundler F. Ghrelin is expressed in a novel endocrine cell type in developing rat islets and inhibits insulin secretion from INS-1 (832/13) cells. J. Histochem. Cytochem. 52, 301-310 (2004).
15. + signaling in b-cells: implication in the glycemic control in rodents. Diabetes 53, 3142-3151 (2004).
16. Kageyama H, Funahashi H, Hirayama M et al. Morphological analysis of ghrelin and its receptor distribution in the rat pancreas. Regul. Pept. 126, 67-71 (2005).
17. Egido EM, Rodriguez-Gallardo J, Silvestre RA, Marco J. Inhibitory effect of ghrelin on insulin and pancreatic somatostatin secretion. J. Endocrinol. 146, 241-244 (2002).
18. Doi A, Shono T, Nishi M et al. IA-2b, but not IA-2, is induced by ghrelin and inhibits glucose-stimulated insulin secretion. Proc. Natl Acad. Sci. USA 103, 885-890 (2006).
19. Broglio F, Gottero C, Benso A et al. Effects of ghrelin on the insulin and glycemic responses to glucose, arginine, or free fatty acids load in humans. J. Clin. Endocrinol. Metab. 88, 4268-4272 (2003).
20. Saad MF, Bernaba B, Hwu CM et al. Insulin regulates plasma ghrelin concentration. J. Clin. Endocrinol. Metab. 87, 3997-4000 (2002).
21. Cummings DE, Purnell JQ, Frayo RS et al. A preprandial rise in plasma ghrelin levels suggests a role in meal initiation in humans. Diabetes 50, 1714-1719 (2001).
22. Tolle V, Bassant MH, Zizzari P et al. Ultradian rithmicity of ghrelin secretion in relation with GH, feeding behavior, and sleep-wake patterns in rats. Endocrinology 143, 1353-1361 (2002).
23. Toshinai K, Mondal MS, Nakazato M et al. Upregulation of ghrelin expression in the stomach upon fasting, insulin-induced hypoglycaemia, and leptin administration. Biochem. Biophys. Res. Commun. 281, 1220-1225 (2001).
24. Sun Y, Wang P, Zheng H, Smith RG. Ghrelin stimulation of growth hormone release and appetite is mediated through the growth hormone secretagogue receptor. Proc. Natl. Acad. Sci. USA 101, 4679-4684 (2004).
25. Reimer MK, Pacini G, Ahren B. Dosedependent inhibition by ghrelin of insulin secretion in the mouse. Endocrinology 144, 916-921 (2003).
26. Muller AF, Janssen JA, Hofland LJ et al. Blockade of the growth hormone (GH) receptor unmasks rapid GH-releasing peptide-6- mediated tissue specific insulin resistance. J. Clin. Endocrinol. Metab. 86, 590-593 (2001).
27. Svensson J, Lonn L, Jansson JO et al. Two-month treatment of obese subjects with the oral growth hormone (GH) secretagogue MK-677 increases GH secretion, fat-free mass, and energy expenditure. J. Clin. Endocrinol. Metab. 83, 362-369 (1998).
28. Chapman IM, Bach MA, Van Cauter E et al. Stimulation of the growth hormone (GH)-insulin like growth factor I axis by daily oral administration of a GH secretagogue (MK-677) in healty elderly subjects. J. Clin. Endocrinol. Metab. 81, 4249-4257 (1996).
29. Kojima M Hosoda H, Date Y, Nakazato M, Matsuo H, Kangawa K. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature 402, 656-660 (1999)
30. Jeffery PL, Duncan RP, Yeh AH et al. Expression of the ghrelin axis in the mouse: an exon 4-deleted mouse proghrelin variant encodes a novel C-terminal peptide. Endocrinology 146, 432-440 (2005).
31. Gualillo O, Lago F, Dieguez C. Introducing GOAT: a target for obesity and anti-diabetic drugs? Trends Pharmacol. Sci. 29, 398-401 (2008).
32. Hosoda H, Kojima M, Mizushima Y, Shimizu S, Kangawa K. Structural divergence of human ghrelin. Identification of multiple ghrelin-derived molecules produced by post-translational processing. J. Biol. Chem. 278, 64-70 (2003).
33. Sato T, Fukue Y, Teranishi H, Yoshida Y, Kojima M. Molecular forms of hypothalamic ghrelin and its regulation by fasting and 2-deoxy-d-glucose administration. Endocrinology 146, 2510-2516 (2005).
34. Mondal MS, Date Y, Yamaguchi H et al. Identification of ghrelin and its receptor in neurons of the rat arcuate nucleus. Regul. Pept. 126, 55-59 (2005).
35. Hosoda H, Kojima M, Matsuo H, Kangawa K. Ghrelin and des-octanoil ghrelin: two major forms of rat ghrelin peptide in gastrointestinal tissue. Biochem. Biophys. Res. Commun. 279, 909-913 (2000).
36. Toshinai K, Yamaguchi H, Sun Y et al. Des-acyl ghrelin induces food intake by a mechanism independent of the growth hormone secretagogue receptor. Endocrinology 147, 2306-2314 (2006).
37. Asakawa A, Inui A, Fujimiya M et al. Stomach regulates energy balance via acylated ghrelin and desacyl ghrelin. Gut 54, 18-24 (2005).
38. Chen CY, Chao Y, Chang FY, Chien EJ, Lee SD, Doong ML. Intracisternal des-acyl ghrelin inhibits food intake and non-nutrient gastric emptying in conscious rats. Int. J. Mol. Med. 16, 695-699 (2005).
39. Matsuda K, Miura T, Kaiya H et al. Regulation of food intake by acyl and des-acyl ghrelins in the goldfish. Peptides 27, 2321-2325 (2006).
40. Zhang JV, Ren PG, Avsian-Kretchmer O et al. Obestatin, a peptide encoded by the ghrelin gene, opposes ghrelin's effects on food intake. Science 310, 996-999 (2005).
41. Garg A. Commentary: the ongoing saga of obestatin: is it a hormone? J. Clin. Endocrinol. Metab. 92, 3396-3398 (2007).
42. Soares JB, Leite-Moreira AF. Ghrelin-des-acyl ghrelin and obestatin: three pieces of the same puzzle. Peptides 29, 1255-1270 (2008).
43. Chartrel N, Alvear-Perez R, Leprince J et al. Comment on Obestatin, a peptide encoded by the ghrelin gene, opposes ghrelin's effects on food intake. Science 315, 766c (2007).
44. Zhang JV, Klein C, Ren PG et al. Response to comment on Obestatin, a peptide encoded by the ghrelin gene, opposes ghrelin's effects on food intake. Science 315, 766d (2007)
45. Nargund RP, Patchett AA, Bach MA, Murphy MG, Smith RG. Peptidomimetic growth hormone secretagogues. Design considerations and therapeutic potential. J. Med. Chem. 41, 3103-3127 (1998).
46. MaKee KK, Palyha OC, Feighner SD et al. Molecular analysis of rat pituitary and hypothalamus growth hormone secretagogue receptors. Mol. Endocrinol. 11, 415-423 (1997).
47. Chu KM, Chow KB, Leung PK et al. Overexpression of the truncated ghrelin receptor b polypeptide attenuates the constitutive activation of phosphatidylinositol-specific phospholipase C by ghrelin receptors but has no effect on ghrelin-stimulated extracellular signalregulated kinase 1/2 activity. Int. J. Biochem. Cell. Biol. 39, 752-764 (2007).
48. Barzon L, Pacenti M, Masi G, Stefani AL, Fincati K, Palu G. Loss of growth hormone secretagogue receptor 1a and overexpression of type 1b receptor transcripts in human adrenocortical tumors. Oncology 68, 414-421 (2005).
49. Baldanzi G, Filigheddu N, Cutrupi S et al. Ghrelin and de-acyl ghrelin inhibit cell death in cardiomiocytes and endothelial cells through ERK1/2 and PI3-kinase/AKT. J. Cell Biol. 159, 1029-1037 (2004).
50. Cassoni P, Ghe C, Marrocco T et al. Expression of ghrelin and biological activity of specific receptors for ghrelin and des-acyl ghrelin in human prostate neoplasms and related cell lines. Eur. J. Endocrinol. 150, 173-184 (2004).
51. Muccioli G, Pons N, Ghe C, Catapano F, Granata R, Ghigo E. Ghrelin and des-acyl ghrelin both inhibit isoproterenol-induced lipolysis in rat adipocytes via a non-type 1a growth hormone secretagogue receptor. Eur. J. Pharmacol. 498, 27-35 (2004).
52. Holst B, Cygankiewicz A, Jensen TH, Ankersen M, Schwartz TW. High constitutive signaling of the ghrelin receptor-identification of a potent inverse agonist. Mol. Endocrinol. 17, 2201-2210 (2003).
53. Muccioli G, Baragli A, Granata R, Papotti M, Ghigo E. Heterogeneity of ghrelin/growth hormone secretagogue receptors. Neuroendocrinology 86, 147-164 (2007).
54. Holst B, Lang M, Brandt E et al. Ghrelin receptor inverse agonists: identification of an active peptide core and its interaction epitopes on the receptor. Mol. Pharmacol. 70, 936-946 (2006).
55. Smith RG, Sun Y, Betancourt L, Asnicar M. Growth hormone secretagogues: properties and potential pitfalls. Best Pract. Res. Clin. Endocrinol. Metab. 18, 333-347 (2004).
56. Smith RG, Jiang H, Sun Y. Developments in ghrelin biology and potential clinical relevance. Trends Endocrinol. Metabol. 16, 436-442 (2005).
57. Carpino P. Recent developments in ghrelin receptor (GHS-R1a) agonists and antagonists. Exp. Opin. Ther. Patents 12, 1599-1618 (2002).
58. Levin F, Edholm T, Schmidt PT et al. Ghrelin stimulates gastric emptying and hunger in normal-weight humans. J. Clin. Endocrinol. Metab. 91, 3296-3302 (2006).
59. Sanger GJ. Motilin, ghrelin and related neuropeptides as targets for the treatment of GI disorders. Drug Disc. Today 13, 234-239 (2008).
60. Holst B, Brandt E, Bach A, Heding A, Schwartz TW. Nonpeptide and peptide growth hormone secretagogues act both as ghrelin receptor agonist and as positive or negative allosteric modulators of ghrelin signaling. Mol. Endocrinol. 19, 2400-2411 (2005).
61. Bagnasco M, Tulipano G, Melis MR, Argiolas A, Cocchi D, Muller EE. Endogenous ghrelin is an orexigenic peptide acting in the arcuate nucleus in response to fasting. Regul. Pept. 111, 161-167 (2003).
62. Murakami N, Hayashida T, Kuroiwa T et al. Role for central ghrelin in food intake and secretion profile of stomach ghrelin in rats. J. Endocrinol. 174, 283-288 (2002).
63. Shuto Y, Shibasaki T, Otagiri A et al. Hypothalamic growth hormone secretagogue receptor regulates growth hormone secretion, feeling, and adiposity. J. Clin. Invest. 109, 1429-1436 (2002).
64. Sun Y, Ahmed S, Smith RG. Deletion of Ghrelin impairs neither growth nor appetite. Mol. Cell. Biol. 23, 7973-7981 (2003).
65. Wortley KE, Anderson KD, Garcia K et al. Genetic deletion of ghrelin does not decrease food intake but influences metabolic fuel preference. Proc. Natl Acad. Sci. USA 101, 8227-8232 (2004).
66. Qian SH, Chen D, Weingarth ME et al. Neither agouti-related protein nor neuropeptide Y is critically required for the regulation of energy homeostasis in mice. Mol. Cell. Biol. 22, 5027-5035 (2002).
67. Sun Y, Buttle NF, Garcia JM, Smith RG. Characterization of adult ghrelin and ghrelin receptor knockout mice under positive and negative energy balance. Endocrinology 149, 843-850 (2008)
68. Yoshihara F, Kojima M, Hosoda N, Nakazato M, Kangawa K. Ghrelin: a novel peptide for growth hormone release and feeding regulation. Curr. Opin. Clin. Nutr. Metab. Care 5, 391-395 (2002).
69. Cummings DE, Foster KE. Ghrelin-leptin tango in body-weight regulation. Gastroenterology 124, 1532-1535 (2003).
70. Serby MD, Zhao H, Szczepankiewicz BG et al. 2,4-diaminopyrimidine derivatives as potent growth hormone secretagogue receptor antagonists. J. Med. Chem. 49, 2568-2578 (2006).
71. Holst B, Schwartz TW. Constitutive ghrelin receptor activity as a signalling set-point in appetite regulation. Trends Pharmacol. Sci. 25, 113-117 (2004).
72. Rudolph J, Esler WP, O'Connor S et al. Quinazolinone derivatives as orally available ghrelin receptor antagonists for the treatment of diabetes and obesity. J. Med. Chem. 50, 5202-5216 (2007).
73. Demange L, Boeglin D, Moulin A et al. Synthesis and pharmacological in vitro and in vivo evaluations of novel triazole derivatives as ligands of the ghrelin receptor. 1. J. Med. Chem. 50, 1939-1957 (2007).
74. Moulin A, Demange L, Berge G et al. Toward potent ghrelin receptor ligands based on trisubstituted 1,2,4-triazole structure. 2. Synthesis and pharmacological in vitro and in vivo evaluations. J. Med. Chem. 50, 5790-5806 (2007).
75. Holst B, Mokrosinski J, Lang M et al. Identification of an efficacy switch region in the ghrelin receptor responsible for interchange between agonism and inverse agonism. J. Biol. Chem. 282, 15799-15811 (2007).
76. Ahima RS. Antagonism of ghrelin for glycemic control in type 2 diabetes mellitus? Endocrinology 148, 5173-5174 (2007).
77. Katergari SA, Milousis A, Pagonopoulou O, Asimakopoulos B, Nikolettos N. Ghrelin in pathological conditions. Endocr. J. 55, 439-453 (2008).
78. Bednarek MA, Feighner SD, Pong SS et al. Structure-function studies on the new growth hormone-releasing peptide, ghrelin: minimal sequence of ghrelin necessary for activation of growth hormone secretagogue receptor 1a. J. Med. Chem. 43, 4370-4376 (2000).
79. Torsello A, Ghe C, Bresciani E et al. Short ghrelin peptides neither displace ghrelin binding in vitro nor stimulate GH release in vivo. Endocrinology 143, 1968-1971 (2002).
80. Cheng K, Chan WWS, Barreto A, Convey EM, Smith RG. The synergistic effects of His-d-Trp-Ala Trp-d-Phe-Lys-NH2 on growth hormone (GH)-releasing factorstimulated GH release and intracellular adenosine 3́,5́- monophosphate accumulation in rat primary pituitary cell culture. Endocrinology 124, 2791-2798 (1989).
81. Bondensgaard K, Ankersen M, Thogersen H, Hansen BS, Wulff BSW, Bywater RP. Recognition of privileged structures by G-protein coupled receptors. J. Med. Chem. 47, 888-899 (2004).
82. Chen MH, Steiner MG, Patchett AA et al. Analogs of the orally active growth hormone secretagogue L-162,752. Bioorg. Med. Chem. Lett. 6, 2163-2168 (1996).
83. Howard AD, Feighner SD, Cully DF et al. A receptor in pituitary hypothalamus that functions in growth hormone release. Science 273, 974-977 (1996).
84. Pedretti A, Vistoli G. Modeling of human ghrelin receptor (hGHS-R1a) in its close state and validation by molecular docking. Bioorg. Med. Chem. 15, 3054-3064 (2007).
85. Pedretti A, Villa M, Pallavicini M, Valoti E, Vistoli G. Construction of human ghrelin receptor (hGHS-R1a) model using a fragmental prediction approach and validation through docking analysis. J. Med. Chem. 49, 3077-3085 (2006).
86. Lugar CW, Clay MP, Lindstrom TD et al. Synthesis and biological evaluation of an orally active ghrelin agonist that stimulates food consumption and adiposity in rats. Bioorg. Med. Chem. Lett. 14, 5873-5876 (2004).
87. Pan LC, Carpino PA, Lefker BA et al. Preclinical pharmacology of CP-424,391, an orally active pyrazolinone-piperidine growth hormone secretagogue. Endocrine 14, 121-132 (2001).
88. Carpino PA, Lefker BA, Toler SM et al. Discovery and biological characterization of capromorelin analogues with extended half-lives. Bioorg. Med. Chem. Lett. 12, 3279-3282 (2002).
89. Palucki BL, Feighner SD, Pong SS et al. Spiro(indoline-3,4́- piperidine) growth hormone secretagogues as ghrelin mimetcs. Bioorg. Med. Chem. Lett. 11, 1955-1957 (2001).
90. Li J, Chen SY, Li JJ et al. Discovery of a tetrazole-based growth hormone secretagogue: 4-(hydroxybutyl)carbamic acid 2-(5-(1-(2-amino-2- methylpropionylamino)-2- benzyloxyethyl)tetrazol-1-yl)ethyl ester (BMS-317180). J. Med.Chem. 50, 5890-5893 (2007).
91. Dodge JA, Heiman ML. Ghrelin receptor modulators. Ann. Rep. Med. Chem. 81-88 (2003).
92. Hernandez AS, Cheng PTW, Musial CM et al. Discovery, synthesis and structure-activity studies of tetrazole based growth hormone secretagogues. Bioorg. Med. Chem. Lett.17, 5928-5933 (2007).
93. Li J, Chen SY, Tao S et al. Design and synthesis of tetrazole-based growth hormone secretagogue: the SAR studies of the O-benzyl serine side chain. Bioorg. Med. Chem. Lett. 18, 1825-1829 (2008).
94. Hernandez AS, Swartz SG, Slusarchyk D et al. Optimization of 1H-tetrazole-1-alkanenitriles as potent orally bioavailable growth hormone secretagogues. Bioorg. Med. Chem. Lett. 18, 2067-2072 (2008).
95. Ye Z, Gao Y, Bakshi RK et al. Modeling directed design and biological evaluation of quinazolinones as non-peptidic growth hormone secretagogues. Bioorg. Med. Chem. Lett. 10, 5-8 (2000).
96. Esler WP, Rudolph J, Claus TH et al. Small-molecule ghrelin receptor antagonists improve glucose tolerance, suppress appetite, and promote weight loss. Endocrinology 148, 5175-5185 (2007).
97. Heightman TD, Scott JS, Longley M et al. Potent achiral agonists of the ghrelin (growth hormone secretagogue) receptor. Part I: lead identification. Bioorg. Med. Chem. Lett. 17, 6584-6587 (2007).
98. Witherington J, Abberley L, Briggs MA et al. Potent achiral agonists of the growth hormone secretagogue (ghrelin) receptor. Part 2: lead optimization. Bioorg. Med. Chem. Lett. 18, 2203-2205 (2008).
99. Deghenghi R, Cananzi MM, Torsello A, Battisti C, Muller EE, Locatelli V. GH-releasing activity of hexarelin, a new growth hormone releasing peptide, in infant and adult rats. Life Sci. 54, 1321-1328 (1994).
100. Locatelli V, Rossoni G, Schweiger F et al. Growth hormone-independent cardioprotective effects of hexarelin in the rat. Endocrinology 140, 4024-4031 (1999).
101. Guerlavais V, Boeglin D, Mousseaux D et al. New active series of growth hormone secretagogues. J. Med. Chem. 46, 1191-1203 (2003).
102. Ong H, McNicoll N, Escher E et al. Identification of a pituitary growth hormone-releasing peptide (GHRP) receptor subtype by photoaffinity labeling. Endocrinology 139, 432-435 (1998)
103. Broglio F, Boutignon F, Benso A et al. EP1572: a novel peptide-mimetic GH secretagogue with potent and selective GH-releasing activity in man. J. Endocrinol. Invest. 25, R26-R29 (2002).
104. Piccoli P, Degen L, MacLean C et al. Pharmacokinetics and pharmacodynamic effects of an oral ghrelin agonist in healthy subjects. J. Clin. Endocrinol. Metab. 92, 1814-1820 (2007).
105. Moulin A, Demange L, Ryan J et al. New trisubstituted 1,2,4-triazole derivatives as potent ghrelin receptor antagonists. 3. Synthesis and pharmacological in vitro and in vivo evaluations. J. Med. Chem. 51, 689-693 (2008).
106. Moulin A, Demange L, Ryan J et al. Trisubstituted 1,2,4-triazoles as ligands for the ghrelin receptor: on the significance of the orientation and substitution at position 3. Bioorg. Med. Chem. Lett. 18, 164-168 (2008).
107. Taga T, Hume WE, Umezome T et al. oxindole derivatives as orally active potent growth hormone secretagogues. J. Med. Chem. 44, 4641-4649 (2001).
108. Tokunaga T, Hume WE, Nagamine J, Kawamura T, Taiji M, Nagata R. Structure- activity relationships of the oxindole growth hormone secretagogues. Bioorg. Med. Chem. Lett. 15, 1789-1792 (2005).
109. Liu B, Liu G, Xin Z et al. Novel isoxaxole carboxamides as growth hormone secretagogue receptor (GHS-R) antagonists. Bioorg. Med. Chem. Lett. 14, 5223-5226 (2004).
110. Zhao H, Xin Z, Patel JR et al. Structure- activity relationship studies on tetralin carboxamide growth hormone secretagogue receptor antagonists. Bioorg. Med. Chem. Lett. 15, 1201-1204 (2005).
111. Zhao H, Xin Z, Liu G et al. Discovery of tetralin carboxamide growth hormone secretagogue receptor antagonists via scaffold manipulation. J. Med. Chem. 47, 6655-6657 (2004).
112. Xin Z, Zhao H, Serby MD et al. Synthesis and structure-activity relationships of isoxazole carboxamides as growth hormone secretagogue receptor antagonists. Bioorg. Med. Chem. Lett. 15, 1825-1828 (2005).
113. Liu B, Liu M, Xin Z et al. Optimization of 2,4-diaminopyrimidines as GHS-R antagonists: side chain exploration. Bioorg. Med. Chem. Lett. 16, 1864-1868 (2006).
114. Shoda M, Harada T, Kogami Y et al. Identification of structurally diverse growth hormone secretagogue agonists by virtual screening and structure-activity relationship analysis of 2-formylacetamide derivatives. J. Med. Chem. 47, 4286-4290 (2004).
115. Huang P, Loew GH, Funamizu H, Mimura M et al. Rational design, discovery and synthesis of a novel series of potent growth hormone secretagogues. J. Med. Chem. 44, 4082-4091 (2001).
116. Yang J, Zhao TJ, Goldstein JL, Brown MS: Inhibition of ghrelin O-acyltransferase (GOAT) by octanoilated pentapeptides. Proc. Natl Acad. Sci. USA 105, 10750-10755 (2008).
117. Strasser F, Lutz TA, Maeder MT et al. Safety, tolerability and pharmacokinetics of intravenous ghrelin for cancer-related anorexia/cachexia: a randomised, placebocontrolled, double-blind, double-crossover study. Br. J. Cancer 98, 300-308 (2008).
118. Wagner P. Possible mechanisms underlying the development of cachexia in COPD. Eur. Resp. J. 31, 492-501 (2008).
119. Nagaya N, Miyatake K, Uematsu M et al. Hemodynamic, renal, and hormonal effects of ghrelin infusion in patients with chronic heart failure. J. Clin. Endocrinol. Metab. 86, 5854-5859 (2001).
120. Vestergaard ET, Andersen NH, Hansen TK et al. Cardiovascular effects of intravenous ghrelin infusion in healthy young men. Am. J. Physiol. Heart Circ. Physiol. 293, H3020-H3026 (2007).
121. Vestergaard ET Hansen TK, Gormsen LC et al. Constant intravenous ghrelin infusion in healty young men: clinical pharmacokinetics and metabolic effects. Am. J. Physiol. Endocrinol. Metab. 292, E1829-E1836 (2007).
122. Klok MD, Jacobsdottir S, Drent ML. The role of leptin and ghrelin in the regulation of food intake and body weight in humans: a review. Obesity Rev. 8, 21-34 (2006).